Epicur Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Epicur Pharma's estimated annual revenue is currently $15.1M per year.
- Epicur Pharma's estimated revenue per employee is $201,000
Employee Data
- Epicur Pharma has 75 Employees.
- Epicur Pharma grew their employee count by 27% last year.
Epicur Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Manufacturing Operations and Pharmacist-in-Charge | Reveal Email/Phone |
2 | Director Quality | Reveal Email/Phone |
3 | Director Marketing | Reveal Email/Phone |
4 | Chemistry Manager | Reveal Email/Phone |
5 | Chemistry Analyst lll | Reveal Email/Phone |
6 | Veterinary Specialty Representative | Reveal Email/Phone |
7 | Quality Control Analyst II | Reveal Email/Phone |
8 | Veterinary Sales Representative | Reveal Email/Phone |
9 | Aseptic Manufacturing Supervisor | Reveal Email/Phone |
10 | Lead Quality Assurance Analyst | Reveal Email/Phone |
Epicur Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6.6M | 33 | 32% | N/A | N/A |
#2 | $38M | 189 | 6% | N/A | N/A |
#3 | $6.6M | 33 | 22% | N/A | N/A |
#4 | $4180M | 15242 | 1% | $550M | N/A |
#5 | $17.5M | 87 | 50% | N/A | N/A |
#6 | $6.7M | 125 | -37% | $199.6M | N/A |
#7 | $10.9M | 54 | 15% | N/A | N/A |
#8 | $15.3M | 76 | 33% | N/A | N/A |
#9 | $128.6M | 640 | 16% | N/A | N/A |
#10 | $18.7M | 93 | 21% | N/A | N/A |
What Is Epicur Pharma?
Epicur Pharma, a division of Stokes Healthcare, is a mini-manufacturer, producing drugs such as Tacrolimus Eyedrops, Buprenorphine Injection and Gabapentin tablets. Epicur is overseen by the FDA and is considered a 503B Registered Outsourcing Facility.
keywords:N/AN/A
Total Funding
75
Number of Employees
$15.1M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.7M | 87 | 58% | N/A |
#2 | $27.7M | 90 | 2% | N/A |
#3 | $10.8M | 108 | 26% | N/A |
#4 | $19.2M | 128 | 0% | N/A |
#5 | $32.4M | 129 | 1% | N/A |